{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:05:41Z","timestamp":1776920741944,"version":"3.51.2"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01865-y","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T19:02:37Z","timestamp":1665601357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-9320","authenticated-orcid":false,"given":"Masayuki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Suzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"issue":"7","key":"1865_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"15","key":"1865_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1865_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"key":"1865_CR4","unstructured":"VENCLEXTA\u00ae Highlights of Prescribing Information. https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf (Accessed 16 May, 2022)."},{"key":"1865_CR5","doi-asserted-by":"publisher","first-page":"122176","DOI":"10.1016\/j.jchromb.2020.122176","volume":"1152","author":"ED Eisenmann","year":"2020","unstructured":"Eisenmann ED, Jin Y, Weber RH, Sparreboom A, Baker SD. Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. J Chromatogr B. 2020;1152:122176.","journal-title":"J Chromatogr B"},{"key":"1865_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmac027","author":"T Yasu","year":"2022","unstructured":"Yasu T, Gando Y, Nomura Y, Kosugi N, Kobayashi M. Determination of venetoclax concentration in plasma using high-performance liquid chromatography. J Chromatogr Sci. 2022. https:\/\/doi.org\/10.1093\/chromsci\/bmac027.","journal-title":"J Chromatogr Sci"},{"key":"1865_CR7","unstructured":"VENCLEXTA\u00ae Highlights of Interview Form. https:\/\/a-connect.abbvie.co.jp\/-\/media\/assets\/pdf\/products\/venclexta\/if_Venclexta_j.pdf (Accessed 16 May, 2022)."},{"issue":"7","key":"1865_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/1389200215666141125121511","volume":"15","author":"T Niwa","year":"2014","unstructured":"Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab. 2014;15(7):651\u201379.","journal-title":"Curr Drug Metab"},{"issue":"Suppl 1","key":"1865_CR9","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood-2019-127803","volume":"134","author":"A Maiti","year":"2019","unstructured":"Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, et al. Ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: updated results of a phase II trial. Blood. 2019;134(Suppl 1):2637\u20132637.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1865_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/blood-2019-124437","volume":"134","author":"AH Wei","year":"2019","unstructured":"Wei AH, Garcia JS, Borate U, Fong CY, Baer MR, Nolte F, Peterlin P, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-Na\u00efve patients with higher-risk myelodysplastic syndrome. Blood. 2019;134(Suppl 1):568\u2013568.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1865_CR11","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1182\/blood-2019-122120","volume":"134","author":"A Winters","year":"2019","unstructured":"Winters A, Gutman JA, Purev E, Stevens BM, Pei S, Schowinsky J, Abbott D, et al. Venetoclax and azacitidine for older Newly diagnosed patients with acute myeloid leukemia: a single-institution pilot study using measurable residual disease to guide therapy. Blood. 2019;134(Suppl 1):2638\u20132638.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1865_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood-2019-124994","volume":"134","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, Pollyea DA, Garcia JS, Brunner A, Roncolato F, Borate U, Odenike O, et al. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome. Blood. 2019;134(Suppl 1):565\u2013565.","journal-title":"Blood"},{"issue":"1","key":"1865_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","volume":"52","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, et al. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2022;52(1):29\u201338.","journal-title":"Jpn J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01865-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01865-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01865-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T08:54:34Z","timestamp":1667292874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01865-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":13,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01865-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there are no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"259"}}